A double-blind, placebo-controlled study of chronic periodontitis patients
showed that treatment with Lactobacillus reuteri Prodentis as an adjunct to
standard treatment significantly improved efficacy by 53 per cent.
The aim of the study was to evaluate the effects of Lactobacillus reuteri
Prodentis as an adjunct to scaling and root planing, which is the standard
treatment, in chronic periodontitis patients.
By the end of the 12 week long study 53 per cent fewer sites (surfaces on a
teeth) in patients with deep dental pockets and supplemented by Lactobacillus
reuteri Prodentis was in need for surgery, compared to the placebo group (p <
0.019). A site was considered as in need for surgery if the pocket depth was ≥6
mm or ≥5 mm and bleeding.
After the intervention period it was also concluded that 67 per cent of the
patients in the placebo group fell into the high-risk category for disease
progression, while the corresponding figure for patients supplemented by
Lactobacillus reuteri Prodentis was only 27 per cent (p < 0.027). In the
published article the authors point out that these figures are comparable to
what is reported in different studies using a combination of two different
antibiotics as an adjunct to scaling and root planing.
Among the patients with more serious problems there was significantly more
pocket depth reduction and attachment gain (p < 0.05) in the group supplemented
by Lactobacillus reuteri Prodentis compared to corresponding patients in the
placebo group. The study, which was published online 15 August 2013 in Journal
essionid=D962FB61286EA568FDB107D0E481D971.d01t03), included 30 patients.
“This study is important because it shows that less patients will be in need for
surgery and thus both suffering and money for these periodontitis patients could
be saved with BioGaia ProDentis. The results will also help us further penetrate
dental offices around the world and thereby contribute to the growth of our oral
health business”, says Peter Rothschild, President, BioGaia.
BioGaia ProDentis is sold in more than 20 countries all over the world.
Latest press releases from BioGaia
2013-08-06 FDA approves BioGaia’s request for orphan drug designation
2013-06-18 BioGaia acquires remaining 50 per cent of TwoPac AB
2013-05-30 BioGaia signs agreement with Nestlé for new category of products
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 16 August 2013, 01:30
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.